Genetic Evaluation for Medication Selection (GEMS) Study

Completed

Conditions studied: Dementia, Psychiatric Disorders Mood, Behavior Disorders

In brief

Investigators propose to determine whether knowing details about how a person's genes affect the way medicines work in the brain and body will help doctors pick more effective or safer medicine for that person. Target symptoms are restlessness, agitation, depression and related problems common in people with memory loss and dementia.

Key facts

Study ID

NCT03736057

Run by

University of Alabama at Birmingham

People needed

40

Starts

2016-05-13

Expected to finish

2018-08-14

Last updated by the study team

2019-10-07

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Score <26 on the Alabama Brief Cognitive screen or <24 on the Montreal Cognitive Assessment.
• Have a caregiver/informant/family member who spends at least 10 hours per week with the affected person and who is willing to participate
• Be rated by a caregiver/informant as scoring ≥9 on the Functional Activities Questionnaire, including at least one domain score of 3 (dependent).
• Have BPSD sufficient for the treating clinician to begin or change psychotropic drugs, and of sufficiently mild severity that a delay of 5 days before changing the prescription would not be harmful to the patient.

You may not qualify if…

• BPSD of sufficient severity or intensity that (in clinician's opinion) require immediate medication change or referral for emergency services
• Lack of reliable informant with adequate exposure to patient and ability to communicate with study staff in English

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.